Cormark Issues Pessimistic Forecast for Curaleaf Earnings

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Stock analysts at Cormark decreased their FY2025 earnings per share estimates for shares of Curaleaf in a research note issued to investors on Wednesday, March 5th. Cormark analyst J. Pytlak now expects that the company will post earnings per share of ($0.23) for the year, down from their prior forecast of ($0.19). The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Cormark also issued estimates for Curaleaf’s FY2026 earnings at ($0.16) EPS.

Curaleaf (OTCMKTS:CURLF) last posted its earnings results on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.09. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%. The business had revenue of $331.05 million during the quarter, compared to analyst estimates of $331.87 million.

Separately, Roth Capital upgraded Curaleaf to a “strong-buy” rating in a research note on Sunday, November 10th.

Curaleaf Price Performance

CURLF stock opened at $1.01 on Monday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. Curaleaf has a 1 year low of $0.88 and a 1 year high of $6.40. The firm has a market cap of $667.23 million, a P/E ratio of -3.48 and a beta of 0.57. The stock has a 50-day simple moving average of $1.41 and a 200-day simple moving average of $2.13.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.